Tillotts Pharma AG Introduces the New Technology OPTICORE(TM) (OPTImized COlonic RElease) for Colonic Targeting of Active Molecules for the Treatment of Any Colon Disease

Rheinfelden, Switzerland (ots/PRNewswire) -

Tillotts Pharma AG (Switzerland) introduced a new advanced enteric
coating for solid dosage forms at this year's annual meeting of the
American Association of Pharmaceutical Scientists. The OPTICORE(TM)
coating technology comprises two trigger systems and an accelerator
to allow targeted drug release in the large intestine to improve
local and/or systemic drug bioavailability. The inner coating layer
is designed to accelerate the dissolution of the outer coating,
thereby accelerating the release of the active ingredient as soon as
the tablet reaches the large intestine. The pH-sensitive and
enzyme-sensitive triggers together with the accelerator of the inner
layer are designed to open the tablet precisely at the ileo-colonic
junction to make the active ingredient available. The OPTICORE(TM)
technology is particularly suitable for larger single unit
formulations and offers great potential to address colon targeted
delivery especially in challenging conditions of ulcerative colitis.

With the OPTICORE(TM) technology Tillotts Pharma AG introduces an
advanced coating system for accurate site-specific colonic targeting.
The combination of two physiological triggers for drug release,
supported by a coating dissolution acceleration mechanism is designed
to overcome the inter- and intra-individual variability in
gastrointestinal physiology. It consists of an outer polysaccharide
and polymer coating whose degradation is triggered by either pH or
intestinal bacterial enzymes and an inner layer designated to allow
for the overall bioavailability of the dissolved active ingredient
throughout the target region. The coating has been successfully
applied on tablets, gelatine and Hydroxy-propyl-methyl-cellulose
(HPMC) capsules and the neutron-activation process does not impact
the quality of the drug products.

The OPTICORE(TM) technology is designed for accurate drug delivery
to the colon making it especially suitable for larger single unit
formulations and offers great potential to address a colon targeted
delivery especially in the challenging conditions of UC.

About Tillotts

Tillotts Pharma AG, part of the Japanese Zeria Group, is a
fast-growing specialty pharma company with over 250 employees in
Switzerland and abroad. Tillotts is dedicated to the development,
in/out-licensing and commercialisation of innovative pharmaceutical
products for the digestive system. Tillotts successfully markets its
own products for the treatment of IBD as well as in-licensed
products, in over 65 countries through its affiliates within Europe
and a network of gastroenterology-focused partners throughout the
world.

All trademarks used or mentioned here are protected by law.

About Zeria

Zeria Pharmaceutical Co., Ltd., founded in 1955, based in Tokyo,
Japan, focuses on R&D, manufacturing and sales of prescription drugs
as well as OTC products. The company is listed on the First Section
of Tokyo Stock Exchange (Stock code: 4559). Zeria holds a leading
position within the gastroenterology field in Japan and operates
internationally through a number of subsidiaries.

For more information about Zeria please visit
http://www.zeria.co.jp.

© Copyright Tillotts Pharma AG. All rights reserved.

Tillotts Pharma AG media contact:

Suzanne Rouden

Corporate Communications Manager a.i.

Phone: +41(0)61-935-2749

Email: srouden@tillotts.com
http://www.tillotts.com

ots Originaltext: Tillots Phama AG
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Tillots Phama AG, übermittelt durch news aktuell